• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

    8/14/24 4:40:48 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care
    Get the next $VERO alert in real time by email
    SC 13D/A 1 d883019dsc13da.htm SC 13D/A SC 13D/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 12)

     

     

    Venus Concept, Inc.

    (Name of Issuer)

    Common Stock

    (Title of Class of Securities)

    92332W204

    (CUSIP Number)

    R. Scott Barry

    EW Healthcare Partners, L.P.

    21 Waterway Avenue, Suite 225

    The Woodlands, Texas 77380

    (281) 364-1555

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    August 13, 2024

    (Date of Event which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

     

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


     1   

     NAME OF REPORTING PERSON

     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

     EW Healthcare Partners, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     WC

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     4,637,181 (1)

        8   

     SHARED VOTING POWER

     

     -0-

        9   

     SOLE DISPOSITIVE POWER

     

     5,007,087 (1)

       10   

     SHARED DISPOSITIVE POWER

     

     -0-

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     5,007,087 (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     44.6%

    14  

     TYPE OF REPORTING PERSON

     

     PN

     

    (1)

    See Item 5 below.


     1   

     NAME OF REPORTING PERSON

     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

     EW Healthcare Partners-A, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     WC

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     186,564 (1)

        8   

     SHARED VOTING POWER

     

     -0-

        9   

     SOLE DISPOSITIVE POWER

     

     201,447 (1)

       10   

     SHARED DISPOSITIVE POWER

     

     -0-

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     201,447 (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     2.7%

    14  

     TYPE OF REPORTING PERSON

     

     PN

     

    (1)

    See Item 5 below.


     1   

     NAME OF REPORTING PERSON

     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

     Essex Woodlands Fund IX-GP, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     OO

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     4,823,745 (1)

        8   

     SHARED VOTING POWER

     

     -0-

        9   

     SOLE DISPOSITIVE POWER

     

     5,208,534 (1)

       10   

     SHARED DISPOSITIVE POWER

     

     -0-

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     5,208,534 (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     45.8%

    14  

     TYPE OF REPORTING PERSON

     

     PN

     

    (1)

    See Item 5 below.


     1   

     NAME OF REPORTING PERSON

     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

     Essex Woodlands IX, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     OO

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     4,823,745 (1)

        8   

     SHARED VOTING POWER

     

     -0-

        9   

     SOLE DISPOSITIVE POWER

     

     5,208,534 (1)

       10   

     SHARED DISPOSITIVE POWER

     

     -0-

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     5,208,534 (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     45.8%

    14  

     TYPE OF REPORTING PERSON

     

     CO

     

    (1)

    See Item 5 below.


     1   

     NAME OF REPORTING PERSON

     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

     Martin P. Sutter

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     OO

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     -0-

        8   

     SHARED VOTING POWER

     

     4,823,745 (1)

        9   

     SOLE DISPOSITIVE POWER

     

     -0-

       10   

     SHARED DISPOSITIVE POWER

     

     5,208,534 (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     5,208,534 (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     45.8%

    14  

     TYPE OF REPORTING PERSON

     

     IN

     

    (1)

    See Item 5 below.


     1   

     NAME OF REPORTING PERSON

     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

     R. Scott Barry

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     OO

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     -0-

        8   

     SHARED VOTING POWER

     

     4,823,745 (1)

        9   

     SOLE DISPOSITIVE POWER

     

     -0-

       10   

     SHARED DISPOSITIVE POWER

     

     5,208,534 (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     5,208,534 (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     45.8%

    14  

     TYPE OF REPORTING PERSON

     

     IN

     

    (1)

    See Item 5 below.


     1   

     NAME OF REPORTING PERSON

     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

     Ronald Eastman

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     OO

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     -0-

        8   

     SHARED VOTING POWER

     

     4,823,745 (1)

        9   

     SOLE DISPOSITIVE POWER

     

     -0-

       10   

     SHARED DISPOSITIVE POWER

     

     5,208,534 (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     5,208,534 (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     45.8%

    14  

     TYPE OF REPORTING PERSON

     

     IN

     

    (1)

    See Item 5 below.


     1   

     NAME OF REPORTING PERSON

     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

     Steve Wiggins

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     OO

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     -0-

        8   

     SHARED VOTING POWER

     

     4,823,745 (1)

        9   

     SOLE DISPOSITIVE POWER

     

     -0-

       10   

     SHARED DISPOSITIVE POWER

     

     5,208,534 (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     5,208,534 (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     45.8%

    14  

     TYPE OF REPORTING PERSON

     

     IN

     

    (1)

    See Item 5 below.


     1   

     NAME OF REPORTING PERSON

     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

     Petri Vainio

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     SOURCE OF FUNDS

     

     OO

     5  

     CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)

     

     ☐

     6  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

     

        7    

     SOLE VOTING POWER

     

     -0-

        8   

     SHARED VOTING POWER

     

     4,823,745 (1)

        9   

     SOLE DISPOSITIVE POWER

     

     -0-

       10   

     SHARED DISPOSITIVE POWER

     

     5,208,534 (1)

    11   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     5,208,534 (1)

    12  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

     ☐

    13  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

     45.8%

    14  

     TYPE OF REPORTING PERSON

     

     IN

     

    (1)

    See Item 5 below.


    SCHEDULE 13D/A

    Explanatory Note. This Amendment No. 12 (“Amendment No. 12”) amends Amendment No. 11 to Schedule 13D filed on February 28, 2024 (“Amendment No. 11,” and, as amended, the “Amended Schedule 13D”), and relates to the Reporting Persons’ beneficial ownership of shares of the common stock, par value $0.0001 per share (the “Common Stock”), of Venus Concept, Inc. (the “Issuer”). Only those items that are hereby reported are amended; all other items reported in the Amended Schedule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment No. 12 have the meanings ascribed to them in the Amended Schedule 13D.

    Item 1. Security and Issuer.

    (a) Name of Issuer: Venus Concept Inc.

    (b) Address of Issuer’s Principal Executive Office: 235 Yorkland Blvd., Suite 900, Toronto, ON M2J 4Y8

    (c) Title and Class of Securities: Common Stock

    (d) CUSIP Number: 92332W204

    Item 2. Identity and Background.

    (a) This Amendment No. 12 is being filed jointly by EW Healthcare Partners L.P., a Delaware limited partnership (“EWHP”), EW Healthcare Partners-A L.P., a Delaware limited partnership (“EWHP-A”), Essex Woodlands Fund IX-GP, L.P., a Delaware limited partnership ( “Essex IX Fund GP”), Essex Woodlands IX, LLC, a Delaware limited liability company (“Essex IX General Partner”), Martin P. Sutter, an individual, R. Scott Barry, an individual, Ronald Eastman, an individual, Petri Vainio, an individual, and Steve Wiggins, an individual (each a “Manager”, collectively, the “Managers”, and together with the EWHP, EWHP-A, Essex IX Fund GP and the Essex IX General Partner, the “Reporting Persons”).

    (b) Address of Principal Business Office: The address of the principal business of each of the Reporting Persons is 21 Waterway Avenue, Suite 225, The Woodlands, Texas 77380.

    (c) The principal business of EWHP and EWHP-A is growth capital investments. The principal business of Essex IX Fund GP is to act as the general partner of EWHP and EWHP-A. The principal business of Essex IX General Partner is to act as the general partner of Essex IX Fund GP. The principal business of the Managers is to direct the activities of Essex IX General Partner.

    (d) None of the Reporting Persons have, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

    (e) None of the Reporting Persons have, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

    (f) Citizenship: (i) EWHP is a Delaware limited partnership; (ii) EWHP-A is a Delaware limited partnership; (iii) Essex IX Fund GP is a Delaware limited partnership; (iv) Essex IX General Partner is a Delaware limited liability company; (v) the Managers are all individuals who are citizens of the United States.

    Item 4. Purpose of Transaction.

    Due to an administrative error, this Amendment No. 12 corrects the number of shares of Common Stock beneficially owned by the Reporting Persons that are issuable upon conversion of the Notes (as defined below), which was disclosed in Amendment No. 11. This Amendment No. 12 is filed to correct such errors and the related ownership adjustments, and report the Reporting Persons’ beneficial ownership based on the number of shares of the Issuer’s Common Stock outstanding as of August 7, 2024.


    Except as described in this Amendment No. 12 to Schedule 13D, none of the Reporting Persons has any present plan or proposal which relates to, or could result in, any of the events referred to in paragraphs (a) through (j), inclusive, of Item 4 of Schedule 13D. However, the Reporting Persons will continue to review the business of the Issuer and, depending upon one or more of the factors referred to above, may in the future propose that the Issuer take one or more such actions.

    Item 5. Interest in Securities of the Issuer.

    (a)-(b)

    TOTAL OUTSTANDING SHARES. According to the Issuer’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the Securities and Exchange Commission (the “SEC”) on August 13, 2024, the number of shares of the Issuer’s Common Stock outstanding on August 7, 2024 was 7,255,277 shares.

    EWHP INVESTORS. As of the date of filing of this Amendment No. 12, the Reporting Persons are the beneficial owners of (i) 1,089,190 shares of the Issuer’s Common Stock (1,047,064 shares held by EWHP and 42,126 shares held by EWHP-A), (ii) 1,000,050 shares of the Issuer’s Common Stock (961,370 shares held by EWHP and 38,680 shares held by EWHP-A), issuable upon conversion of 1,500,000 shares of Voting Convertible Preferred Stock, par value $0.0001 per share, of the Issuer (1,441,983 shares held by EWHP and 58,017 shares held by EWHP-A), acquired in November 2022 (the “Junior Preferred Stock”), (iii) 1,090,403 shares of the Issuer’s Common Stock (1,048,230 shares held by EWHP and 42,173 shares held by EWHP-A), issuable upon conversion of the Senior Convertible Preferred Stock, par value $0.0001 per share, of the Issuer (“Senior Preferred Stock”), which are convertible within 60 days of the date hereof (for the avoidance of doubt, these shares are subject to limitations on convertibility imposed by the rules and regulations of the Nasdaq Capital Market as noted below), (iv) 12,373 shares of the Issuer’s Common Stock issuable upon the exercise of Warrants held by EWHP-A, which were exercisable beginning on May 7, 2020, (v) 307,539 shares of the Issuer’s Common Stock issuable upon the exercise of Warrants held by EWHP, which were exercisable beginning September 16, 2020, (vi) stock options issued to R. Scott Barry to purchase 6,676 shares of the Issuer’s Common Stock (6,418 shares held for the benefit of EWHP and 258 shares held for the benefit of EWHP-A), which will be exercisable within 60 days of the date hereof, and (vii) 1,702,203 shares of Common Stock issuable upon conversion of secured subordinated convertible notes (“Notes”) (1,636,466 shares held by EWHP and 65,837 shares held by EWHP-A), which are convertible within 60 days of the date hereof, and which amount is inclusive of 103,582 shares of Common Stock issuable to pay accrued interest on the Notes (calculated through June 30, 2024) and payable as of the date of filing of this Amendment No. 12 (99,576 shares held by EWHP and 4,006 shares held by EWHP-A).

    The shares of the Issuer’s Common Stock shown to be beneficially owned before the date of this filing exclude (a) 2,991,458 shares of the Issuer’s Common Stock issuable upon conversion of 1,121,783 shares of Senior Preferred Stock held by EWHP and (b) 120,352 shares of the Issuer’s Common Stock issuable upon conversion of 45,131 shares of Senior Preferred Stock held by EWHP-A, as such conversions cannot occur within 60 days after the date hereof due to limitations on convertibility imposed by the rules and regulations of the Nasdaq Capital Market.

    (a) Regarding aggregate beneficial ownership, see Row 11 of the cover page of each Reporting Person. The number of shares listed in Row 9, Row 10 and Row 11 for each Reporting Person includes the shares of Common Stock held by the Reporting Person, shares of Common Stock issuable upon conversion of shares of Junior Preferred Stock held by the Reporting Person, shares of Common Stock issuable upon conversion of shares of Senior Preferred Stock held by the Reporting Person within 60 days of the date hereof (subject to limitations on convertibility imposed by the rules and regulations of the Nasdaq Capital Market), shares of Common Stock issuable upon the exercise of the Warrants held by the Reporting Person, shares of Common Stock issuable upon exercise of the stock options held by the Reporting Person, and shares of Common Stock issuable upon the conversion of the Convertible Notes held by the Reporting Person.

    Regarding percentage beneficial ownership, see Row 13 of the cover page of each Reporting Person. The percentage listed in Row 13 for each Reporting Person was calculated including 7,255,277 shares of the Issuer’s Common Stock outstanding as of August 7, 2024, plus 1,000,050 additional shares of the Issuer’s Common Stock, which are issuable upon conversion of the Junior Preferred Stock held by the Reporting Persons (961,370 shares held by EWHP and 38,680 shares held by EWHP-A), plus 1,090,403 additional shares of the Issuer’s Common Stock (1,048,230 shares held by EWHP and 42,173 shares held by EWHP-A), which are issuable upon conversion of the Senior Preferred


    Stock held by the Reporting Persons within 60 days of the date hereof (for the avoidance of doubt, these shares are subject to limitations on convertibility imposed by the rules and regulations of the Nasdaq Capital Market described in above), plus 319,912 additional shares of the Issuer’s Common Stock which are issuable upon exercise of the Warrants held by the Reporting Persons (307,539 shares held by EWHP and 12,373 shares held by EWHP-A), plus 6,676 additional shares of the Issuer’s Common Stock which are issuable upon exercise of the options issued to R. Scott Barry as a director for benefit of the Reporting Persons (6,418 shares held for the benefit of EWHP and 258 shares held for the benefit of EWHP-A) and exercisable within the next 60 days of the date hereof, plus 1,702.303 shares of Common Stock issuable upon conversion of the Notes (1,636,466 shares held by EWHP and 65,837 shares held by EWHP-A), which are convertible within 60 days of the date hereof, and which amount is inclusive of 103,582 shares of Common Stock issuable to pay accrued interest on the Notes (calculated through June 30, 2024) and payable as of the date of this prospectus (99,576 shares held by EWHP and 4,006 shares held by EWHP-A).

    All amounts are treated as converted into Common Stock only for the purpose of computing the percentage ownership of each Reporting Person.

    (c) None.

    (d) and (e) not applicable.

    Item 7. Material to be filed as Exhibits.

    Exhibit 1: Joint Filing Agreement, dated August 14, 2024


    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    Date: August 14, 2024

     

    EW HEALTHCARE PARTNERS, L.P.     INDIVIDUALS:
    By:   Essex Woodlands Fund IX-GP, L.P.,    
      Its General Partner    
         
    By:   Essex Woodlands IX, LLC,     /s/ Martin P. Sutter
      Its General Partner     Name: Martin P. Sutter
    By:   /s/ R. Scott Barry     /s/ R. Scott Barry
      Name: R. Scott Barry     Name: R. Scott Barry
      Title: Manager    
    EW HEALTHCARE PARTNERS-A, L.P.     /s/ Ronald W. Eastman
          Name: Ronald W. Eastman
    By:   Essex Woodlands Fund IX-GP, L.P.,    
      Its General Partner    
    By:   Essex Woodlands IX, LLC     /s/ Petri Vainio
      Its General Partner     Name: Petri Vainio
    By:   /s/ R. Scott Barry     /s/ Steve Wiggins
      Name: R. Scott Barry     Name: Steve Wiggins
      Title: Manager    
    ESSEX WOODLANDS FUND IX-GP, L.P.    
    By:   Essex Woodlands IX, LLC,    
      Its General Partner    
    By:   /s/ R. Scott Barry    
      Name: R. Scott Barry    
      Title: Manager    
    ESSEX WOODLANDS IX, LLC    
    /s/ R. Scott Barry    
    Name: R. Scott Barry    
    Title: Manager    
    Get the next $VERO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VERO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VERO
    Financials

    Live finance-specific insights

    See more
    • Venus Concept to Release First Quarter of Fiscal Year 2025 Financial Results on May 15, 2025

      TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that first quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, May 15, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on May 15, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13753054. A live webcast of the call will also be provided on the investor relations section of the Company's websi

      4/7/25 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept to Release Fourth Quarter and Fiscal Year 2024 Financial Results on March 31, 2025

      TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that fourth quarter and fiscal year 2024 financial results will be released before the market opens on Monday, March 31, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on March 31, 2025 to discuss the results of the quarter and the year with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13751985. A live webcast of the call will also be provided on the investor relations section of the

      3/3/25 4:05:00 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept to Release Third Quarter of Fiscal Year 2024 Financial Results on November 13, 2024

      TORONTO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that third quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday, November 13, 2024. Management will host a conference call at 8:00 a.m. Eastern Time on November 13, 2024 to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13749236. A live webcast of the call will also be provided on the investor relations section of the Company's

      10/2/24 4:05:00 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    SEC Filings

    See more
    • Venus Concept Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Venus Concept Inc. (0001409269) (Filer)

      6/6/25 5:07:51 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Venus Concept Inc. (0001409269) (Filer)

      6/2/25 4:28:55 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Venus Concept Inc.

      SD - Venus Concept Inc. (0001409269) (Filer)

      5/30/25 7:00:18 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

      SC 13D/A - Venus Concept Inc. (0001409269) (Subject)

      10/8/24 7:51:38 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

      SC 13D/A - Venus Concept Inc. (0001409269) (Subject)

      10/3/24 7:59:41 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Venus Concept Inc.

      SC 13G/A - Venus Concept Inc. (0001409269) (Subject)

      9/30/24 9:53:26 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $VERO
    Leadership Updates

    Live Leadership Updates

    See more

    $VERO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Venus Concept Announces Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

      TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase and sale of 434,720 shares of common stock at a purchase price of $2.65 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered short-term warrants to purchase up to 869,440 shares of common stock at an exercise price of $2.65 per share that will be immediately exercisable upon issuance and will expire eighteen months following the effective date of the regist

      6/6/25 11:35:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Announces Definitive Agreement to Sell Venus Hair Business for $20 Million

      TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today it has entered into a definitive agreement to sell its Venus Hair business to MHG Co. Ltd ("Meta Healthcare Group") in an all-cash transaction valued at $20 million, subject to a customary working capital adjustment. The net proceeds from the transaction, once completed, will enhance the Company's balance sheet and financial condition and provide valuable capital to fund strategic growth initiatives. "We are pleased to announce one outcome of our evaluation of strategic alternatives to maximize shareholder value," sai

      6/6/25 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Announces First Quarter 2025 Financial Results

      TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced financial results for the three months ended March 31, 2025. Summary of Financial Results & Recent Progress: Total revenue for the first quarter of $13.6 million, down 22% year-over-year, reflecting continued difficult market conditions. First quarter operating expenses declined 6% year-over-yearFirst quarter GAAP net loss of $12.4 million, compared to $9.8 million last yearFirst quarter Adjusted EBITDA loss of $8.3 million, compared to $5.1 million last year On April 1, 2025, the Company exchanged $11.0 million of its sub

      5/15/25 7:00:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Inc. Appoints Dr. Hemanth Varghese as President and Chief Operating Officer and Industry Veteran to Lead International Operations

      TORONTO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the promotion of Dr. Hemanth Varghese to the newly created role of President and Chief Operating Officer (COO), reporting to Chief Executive Officer, Rajiv De Silva, effective October 16, 2023. Dr. Varghese joined Venus Concept in October of 2022 as President and Chief Business Officer. His responsibilities were later expanded to include the Chief Innovation Officer role as well. Dr. Varghese has been pivotal in developing and executing the Company's turnaround strategy. In his new role, Dr. Varghese will assume

      10/12/23 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Appoints Dr. Hemanth Varghese as President & Chief Business Officer

      TORONTO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Dr. Hemanth Varghese to the position of President & Chief Business Officer, effective October 17, 2022. "We are delighted to have Hemanth join Venus Concept at this pivotal time for the Company," said Rajiv De Silva, Chief Executive Officer and Director of Venus Concept. "Hemanth is an accomplished healthcare executive with a 20-year track record of performance and execution. He is a versatile leader with experience leading diverse healthcare businesses in high-growth markets in North America and in

      10/11/22 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Appoints Ross J. Portaro as President of Global Sales

      TORONTO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Ross J. Portaro to the position of President of Global Sales, effective October 15, 2021. Mr. Portaro will assume the responsibilities of Chad A. Zaring, who is resigning from his role of Chief Commercial Officer for personal reasons, effective October 15, 2021. Mr. Zaring will continue to support the Company as a consultant through March 31, 2022. "Ross is an accomplished leader and industry veteran with more than 30 years of experience in the healthcare sector, including positions at Candela Med

      10/12/21 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Large owner Madryn Asset Management, Lp

      4 - Venus Concept Inc. (0001409269) (Issuer)

      4/2/25 5:47:31 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Director Natale Anthony sold $13,194 worth of shares (42,768 units at $0.31) (SEC Form 4)

      4 - Venus Concept Inc. (0001409269) (Issuer)

      12/4/24 5:43:14 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Large owner Masters Michael Willingham sold $179,641 worth of shares (306,135 units at $0.59) (SEC Form 4)

      4 - Venus Concept Inc. (0001409269) (Issuer)

      10/2/24 7:54:31 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care